The Food and Drug Administration (FDA) has issued an urgent recall for shellstock oysters harvested by Ruco's Shellfish in Washington state's Hammersley Inlet between December 2 and 17, citing ...

The subcutaneous approval covers nearly all existing solid tumor indications for intravenous Opdivo with the exception of its combo uses with Yervoy.

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

Bizengri received accelerated approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, showing ORRs of 33% and 40%, respectively, with varying DORs. Imfinzi significantly improved ...

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

Rich Scherr is a seasoned journalist and editor who has traveled across the U.S., Canada, and Europe, and spent more than a decade reviewing hotel room.

2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...

Rebecca Dancer is a full-time writer living in Los Angeles. She writes for a variety of publications, covering everything from beauty and wellness to fashion and lifestyle. Taylor has been an ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.